anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Urinary Incontinence (UI) is a global health issue that mainly affects the female population worldwide. Different approaches have been sought for the management of UI including Pelvic floor muscle training (PFMT) using Virtual Reality (VR) gaming. We conducted this study to evaluate the effectiveness of VR gaming for rehabilitation of pelvic floor muscles (PFM) and improving urinary symptoms in patients with UI.
METHOD: We've included studies that contain any type of VR in all geographic locations and settings with no restrictions on the date of publication, age, or gender. Our exclusion criteria include reviews, case series, case reports, unextractable data, unavailable full text, abstract only articles, and studies don't show the effects of VR as a treatment for UI. A pre-specified search term was used and modified according to the requirements of each of the following databases: PubMed, Web of Science, Scopus, Cochrane, Google scholar, and ScienceDirect. For risk of bias assessment, two assessment tools have been used: ROB 2.0 for RCTs and NIH for single arm studies.
RESULTS: Of 915 papers identified from 6 databases, 341 papers were assigned for screening after removing duplicates, 11 papers were eligible for full text screening, and 4 papers were finally included. The qualitative analysis of the results identifies six outcomes grouped into three primary categories: PFM, urinary symptoms, and quality of life. Only urinary loss outcome was eligible for meta-analysis. The net effect between Game therapy + PFMT and PFMT reached MD = -5.49, 95% CI [-12.36:1.38] (heterogeneity; I2 = 95%, p < 0.01).
CONCLUSION: Our research underscores the potential of VR gaming as a valuable adjunctive therapy for pelvic floor muscle rehabilitation in patients with UI. However, further studies are needed to explore its long-term effectiveness, optimal therapy parameters, and cost-effectiveness.
REGISTRATION: Our protocol has been registered in PROSPERO (CRD42022384500).
Ten fire departments from across the nation (8 career, 2 volunteer) were recruited for this study. In Aims 1 and 2, program evaluation methods were used to examine the implementation and acceptability of the SFAI intervention components. These evaluation methods were based on standard practices which employs a systematic method for collecting, analyzing, and using information to answer questions about the implementation and acceptability of the SFAI. In Aim 3 a pilot CRCT was conducted comparing the SFAI versus control (delayed treatment) on key behavioral health outcomes. Four career departments were randomized to the SFAI condition and 4 to the control condition. Statistical power analysis was based on these 8 career departments and will provide the primary project outcomes. Between groups outcomes were assessed at 12-months.
BACKGROUND: Total hip arthroplasty (THA) is a common procedure that requires consideration of preexisting comorbidities. Factor V Leiden (FVL), an inherited thrombophilia, is one such condition that predisposes patients to venous thromboembolism (VTE, deep vein thrombosis, and pulmonary embolism). The present study aimed to characterize the risks associated with FVL patients undergoing THA and evaluate the effect of VTE chemoprophylactic agents on these risks.
METHODS: A total of 544,022 adult patients who underwent primary THA for osteoarthritis indications between 2010 and October 2021 were identified in an administrative claims database. Of these, FVL was identified in 1,138 (0.21%). Patients who had and did not have FVL were matched at a 1:4 ratio (1,131 with FVL and 4,519 without FVL) based on age, sex, and Elixhauser comorbidity index. Univariable and multivariable analyses were assessed for 90-day complications. Implant survival at 5 years was assessed and compared with log-rank tests. The relative use of different chemoprophylactic agents, including aspirin, warfarin, heparin, or direct oral anticoagulant (DOAC), was assessed. Bleeding events and VTE were compared for those prescribed either aspirin or warfarin, heparin, or DOAC. A Bonferroni correction was applied.
RESULTS: On multivariable analysis, FVL patients were found to have increased odds of 90-day deep vein thrombosis (odds ratio (OR) = 9.20), pulmonary embolism (OR = 6.89), and aggregated severe and all adverse events (OR = 4.74 and 1.98, respectively), but not elevated risk of other perioperative adverse events or 5-year reoperations. More potent chemoprophylactic agents (warfarin, heparin, DOAC) reduced, but did not completely eliminate, the increased VTE risks (without increasing bleeding events).
CONCLUSIONS: This study quantified the significantly elevated VTE risk associated with FVL patients undergoing THA. The lack of difference in other specific adverse events and 5-year reoperations is reassuring. Clearly, chemoprophylactic agents are important in this population and may need further attention.
Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 6 months.
OBJECTIVE: The BRCA1/2 mutation status testing is the global standard of care for breast cancer patients with a family history of cancer. BRCA1/2 mutations are known to be ethno-specific. For some ethnic groups of the Northern Asia (Buryats, Yakuts, Altaians, Tuvans, Khakasses, etc.) the founder mutations in the BRCA1/2 genes have not been revealed. This systematic review was conducted to assess the prevalence of BRCA1/2 mutation in breast cancer patients inhabiting Eastern Europe and Northern Asia (or Siberia).
METHODS: A total of 23,561 studies published between 2014 and 2024 were analyzed, of which 55 were included in the review. The literature search was conducted using RusMed, Cyberleninka, Google Scholar, eLibrary, NCBI databases (n=5) and conference papers.
RESULTS: The founder mutations (c.5266dupC and/or c.181T>G) of BRCA1 gene that were frequently observed in the Slav peoples were also identified in Chechens, Armenians, Bashkirs, Ukrainians, Mordovians, Mari, Kabardians, Tatars, Uzbeks, Kyrgyz, Ossetians, Khanty indigenous peoples and Adygs. For Chechens, Kabardians, Ingush, Buryats, Khakasses, Sakha, Tuvans and Armenians, rare pathogenic variants of the BRCA1/2, ATM, СНЕК2, BRIP1, NBN, PTEN, TP53, PMS1, XPA, LGR4, BRWD1 and PALB2 genes were found. No data are available about the frequency of pathogenic BRCA1/2 mutations for ethnic groups, such as the Udmurts, Komi, Tajiks, Tabasarans, and Nogais indigenous people.
CONCLUSION: This is the first systematic review that provides the spectrum of BRCA mutations in ethnic groups of breast cancer patients inhabiting Eastern Europe and Northern Asia. It has been shown that the mutations are ethnospecific (varied widely within groups) and not all groups are equally well studied. Further studies on the ethnic specificity of BRCA gene mutations are required.
Clinicians expect that talking to patients with obesity about potential/future weight loss will be a difficult conversation, especially if it is not the reason that a patient is seeking medical help. Despite this expectation, many governments ask clinicians to take every opportunity to talk to patients about weight to help manage increasing levels of obesity. Although this is recommended, little is known about what happens in consultations when clinicians opportunistically talk to patients about weight, and if the anticipated difficulties are reality. This paper examines displays of explicit patient resistance following opportunistic weight-loss conversations initiated by GPs. We analyzed audio recordings and transcribed them for conversation analysis. We focused on the precursors of explicit resistance displays during opportunistic weight loss discussions, the format of the resistance, and the ways it was managed by GPs. We found relatively few instances of explicit resistance displays. When it did occur, rather than be related to the opportunistic nature of the advice, or the topic of weight itself, resistance was nuanced and associated to the sensitivity of the GPs managing unknown patient levels of awareness of weight loss benefits, or prior efforts to lose weight. Clinicians tended not to challenge this resistance from patients, and we suggest this tactic may be acceptable to patients and help foster the long-term collaborative relationships needed to tackle obesity. Data are in British English.
Recently, the wild deer population has been increasing in Japan, causing serious feeding-related damage to the agricultural and forestry industries. In conjunction with the government's promotion of hunting for population control, the effective utilization of resources and promotion of the game meat industry as a sixth sector of industrialization are desired by local governments. However, several cases in which patients showed intestinal symptoms such as diarrhea due to the consumption of sika deer meat infected with protozoan Sarcocystis spp. have been reported, and the pathogenic microorganisms found in wild deer should be investigated. In this study, Sarcocystis sp. parasitized Kyushu sika deer (Cervus nippon nippon) in Nagasaki Prefecture, Japan, was examined for its enterotoxicity. A phylogenetic analysis based on the sequence of the 18S rRNA gene and cox1 showed that the species was highly homologous to Sarcocystis japonica and/or Sarcocystis sp. HM050622. We attempted to confirm the diarrhea-evoking toxicity of Sarcocystis sp. in sika deer meat, which has been previously reported in human case reports. A mouse ileal loop assay showed that Sarcocystis sp. in sika deer meat induced significant fluid accumulation in the loop at doses of ∼5 × 106 bradyzoites. Western blotting showed that these Sarcocystis parasites possess actin-depolymerizing factor, a diarrhea-evoking factor, similar to Sarcocystis fayeri, which exists in horsemeat. However, the pathogenic conditions of the ileal loop were different from those of similar experiments with S. fayeri. This study suggests that S. japonica parasitizing C. n. nippon may cause diarrhea via a different mechanism from that of S. fayeri.
The present invention comprises compositions and preparations for the promotion of wound healing in an animal. Methods for preparing the compositions as well as methods for using the compositions to achieve the promotion of wound healing, are also provided. The composition may comprise a dietary regimen or a therapeutic agent. These compositions include a wound healing promoting concentration of nucleotides. By way of example, such nucleotides may comprise RNA, adenine, uracil or a mixture thereof. The compositions can be prepared as suitable for oral, parenteral, intravenous or topical administration. Methods for using the preparation as a treatment to enhance the healing of an already existing wound or for use as a pretreatment regimen for animals in anticipation of surgery, are also disclosed.
SPRITAM is intended to disintegrate in the mouth when taken with a sip of liquid. As a primary method of administration, place tablet on the tongue with a dry hand, follow with a sip of liquid and swallow only after the tablet disintegrates. Do not swallow tablet(s) intact. Partial tablet(s) should not be administered. SPRITAM disintegrates in a mean time of 11 seconds (ranging from 2 to 27 seconds) in the mouth when taken with a sip of liquid.

Alternately, add whole SPRITAM tablet(s) to a small volume of liquid in a cup (one tablespoon or enough to cover the medicine). Allow the tablet(s) to disperse prior to consuming the entire contents immediately. After administration of the suspension, re-suspend any residue by adding an additional small volume of liquid and swallow the full amount. No attempt should be made to administer partial quantities of the dispersed tablet(s).

Administer SPRITAM orally, with or without food. The SPRITAM dosing regimen depends on the indication, age group, and renal function.

Patients should be instructed not to push the tablet through the foil. The foil should be peeled from the blister by bending up and lifting the peel tab around the blister seal.
PROBLEM TO BE SOLVED: To obtain an antiallergic agent exhibiting remarkable effects on bronchial-asthma which is an allergic disease, atopic dermatitis and allergic rhinitis and hardly having adverse effects by including extract of Melastma dodecandrum Lour. as active ingredient. SOLUTION: This antiallergic agent contains an extract of Melastma dodecandrum Lour. as an active ingredient. The extract is obtained by crudely cutting whole grass or root of Melastma dodecandrum Lour. in dried or undried state, adding 3-5 pts. wt. solvent such as water-containing acetone to 1 pt.wt. Melastma dodecandrum Lour and subjecting Melastma dodecandrum Lour. to cold immersion and extraction or the like at 15-25 deg.C for 2-3 days, concentrating the extract at <=40 deg.C, subjecting the concentrate to column chromatography and drying the resultant material under reduced pressure. The medicine has remarkable effect in histamine isolation suppressing action and leukotriene isolation suppressing action and is useful for preventing and treating food allergy, inflammation or the like.
PURPOSE:The titled vaccine strain, obtained by attenuating a Lister strain of vaccinia viruses by cell cultivation, and having almost the same antibody production ability as that of the conventional smallpox strain with very weak side reactions of the vaccination. CONSTITUTION:The Lister strain of a parent strain is subcultured in rabbit renal cells at 30 deg.C through 36 passages, and plaque purification is carried out 3 times to separate 50 clones. Temperature-sensitive variant strains, established from renal cells of a green monkey at 40 deg.C, having the worst growth for Vero cells are selected from the 50 clones. The resultant variant strains are then subcultured in rabbit renal cells through 6 passages, and plaque purification is carried out twice to separate uniform clones having relatively small pocks on a hatched chicken egg allanto chorion. The resultant clones are then subcultured in rabbit renal cells at 30 deg.C through 3 passages to separate clones having very small pocks on the hatched chicken egg allantochorion. Thus the aimed attenuated variola vaccine strain is obtained without recognized invasiveness on the central nervous system by peripheral infection of mice.
A method and a system based on matrix check for rapidly determining rational use of a medicine are provided. Attribute values of a medicine are established. The medicine attribute values are added to nodes starting from a root node. A range of attribute values is set, to obtain a determination standard for the attribute values. Data in a tree structure is obtained, and then is split according to different dimensions. A value is defined for each of the different dimensions. The tree structure is traversed to obtain values of each two attributes in the different dimensions. The obtained values of different dimensions are marked as subscripts of a multi-dimensional array. A check matrix is constructed by using the multi-dimensional array. A value of an element in the check matrix is extracted. A conclusion about rational use of the medicine is outputted based on the value of the obtained element.
For clinically suspected or confirmed melanoma patients, targeted melanin-specific imaging 18F-PFPN PET/MR was performed. CT was instead when MRI was contraindicated. PET images, clinical characteristics, and follow-up information will be collected for prognostic analyses.
Abnormalities in laboratory tests may include elevations of liver function tests such as alkaline phosphatase, SGOT (AST), SGPT (ALT), lactic dehydrogenase (LDH), and bilirubin. Abnormalities in blood urea nitrogen (BUN) and positive Coombs test have also been reported. Commonly, levels of blood urea nitrogen, creatinine, and uric acid are lower during administration of carbidopa and levodopa than with levodopa.

Carbidopa and levodopa tablets may cause a false-positive reaction for urinary ketone bodies when a test tape is used for determination of ketonuria. This reaction will not be altered by boiling the urine specimen. False-negative tests may result with the use of glucose-oxidase methods of testing for glucosuria.

Cases of falsely diagnosed pheochromocytoma in patients on carbidopa and levodopa therapy have been reported very rarely. Caution should be exercised when interpreting the plasma and urine levels of catecholamines and their metabolites in patients on levodopa or carbidopa and levodopa therapy.
This study has been carried out using a novel mathematical model on the dynamics of tuberculosis (TB) transmission considering vaccination, endogenous re-activation of the dormant infection, and exogenous re-infection. We can comprehend the behavior of TB under the influence of vaccination from this article. We compute the basic reproduction number ( R 0  ) as well as the vaccination reproduction number ( R v  ) using the next-generation matrix (NGM) approach. The theoretical analysis demonstrates that the disease-free equilibrium point is locally asymptotically stable, and the fractional order system is Ulam-Hyers type stable. We perform numerical simulation of our model using the Adams-Bashforth 3-step method to verify the theoretical results and to show the model outputs graphically. By performing data fitting, we observe that our formulated model produces results that closely match real-world data. Our findings indicate that vaccinating a limited segment of the population can effectively eradicate the disease. The numerical simulations also show that vaccination can reduce the number of susceptible and infectious individuals in the population. Moreover, the graphical representations illustrate that the number of infected individuals rises due to both exogenous reinfection and endogenous reactivation.
Participants with AC mCRPC in Cohort C will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with enzalutamide will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
BACKGROUND AND AIM: Small heterodimer partner (SHP, encoded by NR0B2) plays an important role in maintaining bile acid homeostasis. The loss of the hepatic farnesoid X receptor (FXR)/SHP signal can cause severe cholestatic liver injury (CLI). FXR and SHP have overlapping and nonoverlapping functions in bile acid homeostasis. However, the key role played by SHP in CLI is unclear.
METHODS: In this study, an alpha-naphthylisothiocyanate (ANIT)-induced cholestasis mouse model was established. The effect of SHP knockout (SHP-KO) on liver and ileal pathology was evaluated. 16S rRNA gene sequencing analysis combined with untargeted metabolomics was applied to reveal the involvement of SHP in the pathogenesis of CLI.
RESULTS: The results showed that ANIT (75 mg/kg) induced cholestasis in WT mice. No significant morphological changes were found in the liver and ileal tissue of SHP-KO mice. However, the serum metabolism and intestinal flora characteristics were significantly changed. Moreover, compared with the WT + ANIT group, the serum levels of ALT and AST in the SHP-KO + ANIT group were significantly increased, and punctate necrosis in the liver tissue was more obvious. The ileum villi showed obvious shedding, thinning, and shortening. In addition, SHP-KO-associated differential intestinal flora and differential biomarkers were significantly associated.
CONCLUSION: In this study, we elucidated the serum metabolic characteristics and intestinal flora changes related to the aggravation of CLI in SHP-KO mice induced by ANIT.
Devices, systems, and methods for local delivery of chemotherapy, hormonal therapy, or targeted drug/biologic therapy to a target tissue region of an internal body organ of a patient. The catheter forms a sealed process chamber in a natural lumen extending through the target tissue region. Purging air from the chamber and then filling the chamber with a liquid drug solution to achieve a sufficient treatment session time, solution volume, and drug concentration to saturate the target tissue region, thereby providing treatment. The concentration of the drug in the liquid infusion solution can be formulated to approximate the known maximum plasma concentration achieved during systemic delivery of the same drug. An integrated pressure relief circuit may be included to avoid unsafe pressure levels in the isolation chamber. Evacuating the chamber at the end of the treatment session.
FIELD: pharmacy. SUBSTANCE: parent diacetylrhein containing aloe-emodin components is subjected for dispersing in system liquid-liquid with polar organic solvent showing limited mixing with water, for example, with 2-butanone and an aqueous phase at pH value 6.5-7.5. Diacetylrhein is isolated and recrystallized if necessary. The parent diacetylrhein is obtained from sennoside mixture through anthrone compounds which were oxidized to anthraquinone compounds and obtained product is acetylated. Ferric salt (II) is used as preferable oxidizing agent. The obtained diacetylrhein has residual content of aloe-emodin derivatives at amount 20 ppm that is used as an active component in pharmaceutical composition showing antiarthritis, antiinflammatory, antipyretic and analgetic effects. EFFECT: improved method of purification, increased purity of product. 15 cl
Process for isolating peptidic alkaloids of the ergol type, from rye ergot drugs or from submerged cultures of Claviceps purpurea, by extraction and purification of the extract by changing the phase comprises (a) dissolving the crude mixt. of ergot-type peptidic alkaloids in a protic solvent, partic. 1-6C alkanols; (b) sepn. of the precipitated epimers; (c) defatting with a fat solvent, partic. MIBK or butyl acetate and (d) preparing the obtd. prod. Used for isolation of therapeutically-active peptidic alkalids having ergot structure e.g. ergotamine, the three ergotoxine alkaloids, ergocristine, ergocornine and ergocryptine and intermediates for rye ergot dihydroalkaloids. Simple process is suitable for industrial scale production and reduces the number of phase changes in known processes and yields a crystalline (not amorphous) product. The extraction stage with the protic solvent gives an almost quantitative recovery of the dextro-rotatory form. The defatting stage gives a high purity product which can be used in medicament formulations without further purification.